Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chunxia Su

Showing results (211-220 of 223) with videos related to

Pageof 23
Sort By:
Nature Communications|May 6, 2021
Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancerFengying Wu, Jue Fan, Yayi He, et al.
Translational Lung Cancer Research|May 19, 2020
Challenges and countermeasures of thoracic oncology in the epidemic of COVID-19Haoyue Guo, Xiaoxia Chen, Chunxia Su, et al.
Signal Transduction and Targeted Therapy|April 18, 2024
The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trialBo Cheng, Caichen Li, Jianfu Li, et al.
Cell Reports|March 21, 2023
Pharmacological boosting of cGAS activation sensitizes chemotherapy by enhancing antitumor immunityHaipeng Liu, Hang Su, Fei Wang, et al.
Cancer Cell|April 25, 2025
Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclastsJia-Nan Cheng, Zheng Jin, Chunxia Su, et al.
The Lancet. Respiratory Medicine|July 19, 2021
Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trialJianxing He, Chunxia Su, Wenhua Liang, et al.
Therapeutic Advances in Medical Oncology|July 24, 2023
Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populationsJun Wang, Bicheng Zhang, Ling Peng, et al.
Translational Lung Cancer Research|July 23, 2021
International consensus on severe lung cancer-the first editionChengzhi Zhou, Shiyue Li, Jun Liu, et al.
Journal of Thoracic Disease|May 22, 2025
Expert consensus on cancer treatment-related lung injuryXinqing Lin, Hui Guo, Wei Zhao, et al.
Thoracic Cancer|November 14, 2023
Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancerDingzhi Huang, Gen Lin, Qian Chu, et al.
Pageof 23

Showing results (211-220 of 223) with videos related to

Sort By:
Pageof 23
Nature Communications|May 6, 2021
Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancerFengying Wu, Jue Fan, Yayi He, et al.
Translational Lung Cancer Research|May 19, 2020
Challenges and countermeasures of thoracic oncology in the epidemic of COVID-19Haoyue Guo, Xiaoxia Chen, Chunxia Su, et al.
Signal Transduction and Targeted Therapy|April 18, 2024
The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trialBo Cheng, Caichen Li, Jianfu Li, et al.
Cell Reports|March 21, 2023
Pharmacological boosting of cGAS activation sensitizes chemotherapy by enhancing antitumor immunityHaipeng Liu, Hang Su, Fei Wang, et al.
Cancer Cell|April 25, 2025
Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclastsJia-Nan Cheng, Zheng Jin, Chunxia Su, et al.
The Lancet. Respiratory Medicine|July 19, 2021
Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trialJianxing He, Chunxia Su, Wenhua Liang, et al.
Therapeutic Advances in Medical Oncology|July 24, 2023
Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populationsJun Wang, Bicheng Zhang, Ling Peng, et al.
Translational Lung Cancer Research|July 23, 2021
International consensus on severe lung cancer-the first editionChengzhi Zhou, Shiyue Li, Jun Liu, et al.
Journal of Thoracic Disease|May 22, 2025
Expert consensus on cancer treatment-related lung injuryXinqing Lin, Hui Guo, Wei Zhao, et al.
Thoracic Cancer|November 14, 2023
Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancerDingzhi Huang, Gen Lin, Qian Chu, et al.
Pageof 23